IL-2 and Semaglutide Treatment for Alzheimer's Disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Alzheimer's disease using standard diagnostic criteria
- Age 50–86 years old
- Moderate cognitive impairment (MMSE score between 16–26, a standard memory test)
- Acceptable blood work results (liver, kidney, blood cell counts)
- A family member or caregiver available to help administer study drugs and attend visits
- Stable doses of any Alzheimer's or other chronic-disease medications for at least 30 days before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
This study tests whether an oral diabetes medicine called semaglutide can help people with mild-to-moderate Alzheimer's disease. It may work by reducing inflammation or protecting brain cells, and researchers want to see if it slows memory loss.
This trial tests a new approach to treating Alzheimer's disease by improving both treatment and monitoring. It may help people with mild to moderate Alzheimer's who have specific brain changes seen on scans and in spinal fluid tests.
This study tests if a combination of insulin and semaglutide (a diabetes drug) can improve memory and thinking in people with mild cognitive impairment (MCI) who also have metabolic syndrome (a cluster of health issues like large waist, high blood sugar, and high blood pressure). It aims to see if treating blood sugar problems helps protect the brain.
This Phase 1 study tests whether stimulating the immune system (through a receptor called TLR9) is safe and may affect brain changes in people with early Alzheimer’s. It mainly enrolls older adults with memory impairment confirmed by specific amyloid imaging.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Alzheimer Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.